sur ABIVAX (EPA:ABVX)
ABIVAX: Share and voting rights balance sheet as of October 31, 2025
On November 19, 2025, ABIVAX announced details of the number of shares and voting rights comprising its share capital as of October 31, 2025. The company, listed on Euronext Paris, has a share capital of €778,289.18, divided into 77,885,595 shares.
The total number of theoretical and exercisable voting rights amounts to 82,920,728. These figures include voting rights for private shares, in accordance with the recommendations of the AMF (French Financial Markets Authority). Theoretical voting rights are used, in particular, as the basis for calculating threshold crossings.
ABIVAX, specializing in biotechnology, continues the development of treatments for chronic inflammatory diseases, with its main candidate, obefazimod, in phase 3 for moderate to severe ulcerative colitis.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX